Finally, as strong as Molnupiravir’s potential benefits are, it’s still no substitute for vaccination.
The antiviral may be able to reduce the risk of severe infection, hospitalization, and death by 50%. But remember that vaccines do that, too, by 100%.
Furthermore, getting the vaccine is free for all. Molnupiravir, on the other hand, might only be given to people who are at a higher risk of contracting a severe infection. And if the pill successfully obtains Emergency Use Authorization (EUA) in the Philippines, we’re not sure if it will be free.
Merck’s Molnupiravir might just be the world’s first antiviral pill for COVID-19. Their latest study showed that the pill reduced the risk of hospitalization and death by 50%. The pharmaceutical company also said they will seek EUA as soon as possible. They also plan to manufacture the pill for at least 100 countries.
Learn more about Health News here.